Biodexa Pharmaceuticals (BDRX) Non-Current Assets (2013 - 2025)

Biodexa Pharmaceuticals (BDRX) has 13 years of Non-Current Assets data on file, last reported at $7.6 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Assets changed 0.43% year-over-year to $7.6 million; the trailing twelve-month figure through Dec 2025 stood at $7.6 million (changed 0.43% YoY), and the FY2025 full-year result was $7.6 million, down 1.3% from the prior year.
• Non-Current Assets retreated to $7.6 million in Q4 2025, from $7.8 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $8.1 million in Q2 2024 to a low of $873451.5 in Q2 2023.
• A 5-year average of $4.2 million and a median of $3.1 million in 2023 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets sank 36.78% in 2022 and surged 831.22% in 2024, its largest moves.
• Tracing BDRX's Non-Current Assets over 5 years: stood at $1.6 million in 2021, then slumped by 36.78% to $981741.0 in 2022, then soared by 344.0% to $4.4 million in 2023, then surged by 75.79% to $7.7 million in 2024, then slipped by 0.43% to $7.6 million in 2025.
• Business Quant data shows BDRX's Non-Current Assets at $7.6 million in Q4 2025, $7.8 million in Q2 2025, and $7.7 million in Q4 2024.